Cardiogenic shock: Difference between revisions

No edit summary
Line 2: Line 2:
*Leading cause of death in pts w/ MI who reach the hospital alive
*Leading cause of death in pts w/ MI who reach the hospital alive

*[[Myocardial infarction]]
*[[Myocardial infarction]]
**Pump failure
**Pump failure
Line 27: Line 27:
**Aortic insufficiency
**Aortic insufficiency

==Clinical Presentation==
==Clinical Features==
===Physical Exam===
===Physical Exam===
*Assess for signs of CHF
*Assess for signs of [[CHF]]
**elevated JVD, pulmonary edema, S3
**elevated JVD, pulmonary edema, S3
*Assess for valvular disease (MR, critical AS, or aortic regurgitation)
*Assess for [[valvular disease]] ([[MR]], critical [[AS]], or aortic regurgitation)
*Assess e/o end-organ hypoperfusion
*Assess for end-organ hypoperfusion
**cool/mottled extremities, weak pulses, AMS, decreased UOP
**cool/mottled extremities, weak pulses, AMS, decreased UOP
*Assess for pulsus paradoxus (cardiac tamponade)
*Assess for pulsus paradoxus ([[cardiac tamponade]])

==Differential Diagnosis==
{{Shock DDX}}
Line 47: Line 50:
==Differential Diagnosis==
{{Shock DDX}}

***Decreases O2 demand BUT may worsen preload
***Decreases O2 demand BUT may worsen preload
*Coronary perfusion
*Coronary perfusion
Line 94: Line 94:
*[[Ultrasound in Shock and Hypotension]]
*[[Ultrasound in Shock and Hypotension]]

<references />
<references />

[[Category:Critical Care]]
[[Category:Critical Care]]

Revision as of 20:41, 5 October 2015


  • Leading cause of death in pts w/ MI who reach the hospital alive


Clinical Features

Physical Exam

  • Assess for signs of CHF
    • elevated JVD, pulmonary edema, S3
  • Assess for valvular disease (MR, critical AS, or aortic regurgitation)
  • Assess for end-organ hypoperfusion
    • cool/mottled extremities, weak pulses, AMS, decreased UOP
  • Assess for pulsus paradoxus (cardiac tamponade)

Differential Diagnosis



  • Labs
    • Troponin
    • Lactate
    • CBC
    • Chem
    • BNP
      • <100 may rule-out cardiogenic shock
  • ECG
  • CXR
  • TTE


  • General
    • Intubation
      • Decreases O2 demand BUT may worsen preload
  • Coronary perfusion
  1. Small Fluid challenge
  2. Increase inotropy
    1. Titrate to clinical effect
      • Dobutamine or Milrinone:
      1. Use milrinone if pt is on BB
      2. CaCl 1gm
        1. Give if pt is hypocalcemic
  3. Achieve MAP >65


Pressor Initial Dose Max Dose Cardiac Effect BP Effect Arrhythmias Special Notes
Dobutamine 3-5 mcg/kg/min 5-15 mcg/kg/min (as high as 200) [1] Strong ß1 agonist +inotrope +chronotrope, Weak ß2 agonist +weak vasodilatation ) alpha effect minimal HR variable effects Cite error: Invalid <ref> tag; refs with no name must have content. Also Increase SA and AV node fx indicated in decompensated systolic HF, Debut Research 1979[2] Isoproterenol has most Β2 vasodilatory and Β1 HR effects
Dopamine 2 mcg/kg/min 20-50 mcg/kg/min β1 and NorEpi release α effects if > 20mcg/kg/min Arrhythmogenic from β1 effects More adverse events when used in shock compared to Norepi[3]
Epinepherine 0.1-1 mcg/kg/min + inotropy, + chronotropy
Norepinephrine 0.2 mcg/kg/min 0.2-1.3 mcg/kg/min (5mcg/kg/min) [4] mild β1 direct effect β1 and strong α1,2 effects Less arrhythmias than Dopamine[3] First line for sepsis. Increases MAP with vasoconstriction, increases coronary perfusion pressure, little β2 effects.
Milrinone 50 mcg/kg x 10 min 0.375-75 mcg/kg/min Direct influx of Ca2+ channels Smooth muscle vasodilator PDE Inhibitor which increases Ca2+ uptake by sarcolemma. No venodilatory activity
Phenylephrine 100-180 mcg/min then 40-60 mcg/min 0.4-9 mcg/kg/min Alpha agonist Long half life
Vasopressin Fixed Dose 0.01 to 0.04 U/min unknown increases via ADH peptide should not be titrated due to ischemic effects
Methylene blue[5] IV bolus 2 mg/kg over 15 min 1-2 mg/kg/hour Possible increased inotropy, cardiac use of ATP Inhibits NO mediated peripheral vasodilation Don't use in G6PD deficiency, ARDS, pulmonary hypertension
Medication IV Dose (mcg/kg/min) Concentration
Norepinephrine (Levophed) 0.1-2 mcg/kg/min 8mg in 500mL D5W
Dopamine 2-20 mcg/kg/min 400mg in 250 D5W
Dobutamine 2-20 mcg/kg/min 250mg in 250 mg D5W
Epinephrine 0.1-1 mcg/kg/min 1mg in 250 D5W

Other Therapies

  • Transfusion
    • Consider if Hb < 10

Specific Situations

  1. Mitral Regurg
    1. Need to increase forward flow
    2. Dobutamine (contractility)
    3. Nitroprusside (afterload reduction)
  2. MI
    1. PCI or thrombolysis
  3. Aortic Stenosis
    1. Do not give preload reducers such as Nitro
    2. Patients are flow dependent over stenotic value. Flow proportional to degree of stenosis and afterload.
    3. Maintain flow by decreasing afterload (use with extreme caution and in very small carefuly titrated doses)
      1. Nitropruside
      2. Dobutamine
      3. Hydralazine
  4. Toxins
    1. Beta-Blocker Toxicity
    2. Calcium Channel Blocker
    3. Digoxin

See Also


  2. Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine
  3. 3.0 3.1 De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789
  5. Pasin L et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013 Mar;15(1):42-8.